Phosphodiesterase 4 Gene Variant and Salbutamol Response in Persistent Childhood Asthma

Phosphodiesterase 4 Gene Variant and Salbutamol Response in Persistent Childhood Asthma

This study is designed to investigate whether the Phosphodiesterase 4 gene variability could be implicated in the salbutamol responsiveness in asthmatic children.

Patients from 6 to 18 years old with asthma and receiving a treatment by salbutamol according to the usual care will be recruited. Saliva from patients will be collected using Oragen®.DNA OG-575 kit.

Inclusion Criteria:

• Children 6-18 years
• Asthma: confirmed asthma symptoms (wheeze, cough, dyspnea, chest tightness) and evidence for variable airflow limitation (≥ 12% increase in post bronchodilator FEV1, or ≥ 20% decrease in FEV1 post methacholine)
• Spirometry prescribed for follow-up
• Airflow limitation: FEV1<80% and/or FEV1/FVC <80 pre-bronchodilator

Exclusion Criteria:

• no exclusion criteria